---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-055887"
form_type: "8-K"
ticker: "TECH"
cik: "0000842023"
company_name: "BIO-TECHNE Corp"
filed_at: "2026-05-06T23:59:59+00:00"
generated_at: "2026-05-14T23:04:16.343121+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Bio-Techne Q3 revenue down 2% to $311.4M, adj EPS $0.53; declares $0.08 dividend

## Summary
- Revenue $311.4M, down 2% reported and organic; GAAP EPS $0.32 (up from $0.14), adjusted EPS $0.53 (down from $0.56).
- Large pharma grew double-digits for sixth consecutive quarter; U.S. academic market stabilized with low-single-digit growth; emerging biotech spending still lagging.
- Protein Sciences segment sales $226.2M (down 1% reported); segment margin 44.2% vs 45.6%.
- Diagnostics & Spatial Biology segment sales $85.6M (down 4% reported, up 3% organic); segment margin improved to 12.1% from 9.4%.
- Declared quarterly dividend $0.08 per share, payable May 29, 2026 to shareholders of record May 18, 2026.

## SEC filing metadata
- accession: 0001104659-26-055887
- form_type: 8-K
- ticker: TECH
- cik: 0000842023
- company_name: BIO-TECHNE Corp
- filed_at: 2026-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/842023/000110465926055887/0001104659-26-055887-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/842023/000110465926055887/tech-20260506x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-055887
- JSON: https://secwatch.observer/filing/0001104659-26-055887.json
- Plain text: https://secwatch.observer/filing/0001104659-26-055887.txt

## Source-grounded claims
- claim_id: 3d49242a48b7a5b2e469ce23ad0e920dc81156f6
  claim: BIO-TECHNE Corp reported financial results for quarter and nine months ended March 31, 2026.
  evidence_excerpt: A copy of the press release issued by Bio-Techne Corporation on May 6, 2026, describing the results of operations for the quarter and nine months ended March 31, 2026, and its financial condition as of March 31, 2026 is attached hereto as Exhibit 99.1.
  evidence_url: https://www.sec.gov/Archives/edgar/data/842023/000110465926055887/0001104659-26-055887-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.